Atrophin‐1 Function and Dysfunction in Dentatorubral–Pallidoluysian Atrophy

Abstract

AbstractDentatorubral–pallidoluysian atrophy (DRPLA) is a rare, incurable genetic disease that belongs to the group of polyglutamine (polyQ) diseases. DRPLA is the most common in the Japanese population; however, its global prevalence is also increasing due to better clinical recognition. It is characterized by cerebellar ataxia, myoclonus, epilepsy, dementia, and chorea. DRPLA is caused by dynamic mutation of CAG repeat expansion in ATN1 gene encoding the atrophin‐1 protein. In the cascade of molecular disturbances, the pathological form of atrophin‐1 is the initial factor, which has not been precisely characterized so far. Reports indicate that DRPLA is associated with disrupted protein–protein interactions (in which an expanded polyQ tract plays a crucial role), as well as gene expression deregulation. There is a great need to design efficient therapy that would address the underlying neurodegenerative process and thus prevent or alleviate DRPLA symptoms. An in‐depth understanding of the normal atrophin‐1 function and mutant atrophin‐1 dysfunction is crucial for this purpose. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.